Safety and Efficacy of Campath
Campath® (alemtuzumab) is a prescription drug approved to treat a certain type of leukemia known as B-cell chronic lymphocytic leukemia (B-CLL). It belongs to a group of medicines known as monoclonal antibodies.
In a clinical study examining the efficacy of Campath, the drug was shown to extend the period of time leukemia does not progress, more so than chlorambucil (Leukeran®), another leukemia medicine. In the study, people who received Campath went about 14.6 months without their condition getting worse, compared with 11.7 months in people taking chlorambucil.
Campath is a relatively safe medication, although some sort of side effect can be expected. Common reactions include low blood cell counts and fever. Fortunately, such problems are often mild and easily treated.
(Click Campath to learn more about this drug's safety and efficacy, as well as dosing guidelines, what to do in cases of overdose, and more.)